NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes

MONTREAL, July 20, 2021 /PRNewswire/ -- NIMIUM Therapeutics (www.nimium.ca), a Montreal-based biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMDs). The treatment aims to prevent and reverse the adverse effects of excess sugar and caloric intake and to promote healthier aging. The partnership will focus on the early-stage development of glycerol-3-phosphate phosphatase (G3PP) activators.

NewsGuest UserJuly 20, 2021Nimium Therapeutics, Paraza, Collaboration

New life sciences company takes aim at obesity, toxic effects of overnutrition

MONTREAL, July 6, 2021 /CNW/ - A new made-in-Canada life sciences company, Nimium Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases.

NewsGuest UserJuly 6, 2021obesity, adMare BioInnovations, Nimium Therapeutics